Board summary
Key figures
47,655
Registered population
58.9% aged 18–64
19.5%
Aged 65+
ICB 14.9% · England 17.9%
0.8%
In IMD quintile 1
ICB 40.7% · England 21.0%
~292
Core20 residents (est.)
Resident basis; registered basis ~304 · see page 3
6,775
Hypertension register
+8.80% in 3 yrs · England +5.60%
387
SMI register
14.5% of Trafford (LAD)'s
649
COPD register
Reviews -6.96% in 3 yrs
Forecast to 2030
7,940
Hypertension patients, 2030
+1,165 on today
79.3%
QRISK ≥20% on statins, 2030
+6.95pp over 3 yrs
5.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure control trails recent monitoring.
Although 91.0% have a recent reading, under-80 control is 64.5% (England 67.8%), falling 3.5% over 2023 to 2025 (England +3.2%), which may reflect escalation.
Asthma annual reviews sit below all benchmarks.
Annual asthma reviews reach 59.1% against 63.7% in Trafford (LAD), 66.2% in the ICB and 65.7% in England, leaving a scale indicator of 1,199.
Breast screening coverage leads borough and England.
Breast screening coverage reaches 79.9% against 73.1% in Trafford (LAD), 68.8% in the ICB and 69.9% in England, rising +21.1% over 2023 to 2024.
Population, age and ethnicity
Older adults comprise 19.5% of registered patients, exceeding borough, ICB and national benchmarks
Altrincham Healthcare Alliance PCN covers 47,655 registered patients across five practices. Patients aged 65+ represent 19.5% of the list (9,280), above Trafford (LAD) at 17.1%, NHS Greater Manchester Integrated Care Board at 14.9%, and England at 17.9%. Children aged 0–17 represent 21.6% (10,313; England 19.6%), and working-age adults (18–64) comprise 58.9% (28,062). Census resident data show 0.0% Gypsy or Irish Traveller and 0.1% Roma residents. Registered learning disability prevalence is 0.3% (160 patients; England 0.6%), which may reflect coding differences testable by register validation.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Trafford (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Trafford LA) | 2,087 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 64.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Trafford LA) | 950 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Trafford LA) | 22.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 0.8% overall but concentrated entirely within Park Medical Practice
ALTRINCHAM HEALTHCARE ALLIANCE PCN has an average IMD decile of 8.7 (Trafford: 7.0 decile; England: 5.5 decile; NHS Greater Manchester Integrated Care Board: 4.5 decile) and a Core20 share of 0.8% (Trafford: 8.2%; England: 21.0%; NHS Greater Manchester Integrated Care Board: 40.7%). A reconciliation check shows weighted practice Core20 share is 0.64% versus 0.78% PCN-wide (a 0.14 percentage point difference), alongside 292 estimated Core20 residents. Park Medical Practice records 3.9% (304 estimated patients), while the other four practices each record 0.0%.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
387
SMI register
0.80% recorded prevalence
160
Learning disability register
0.33% recorded prevalence
19
Care homes, 809 beds
In the PCN catchment
8.7%
Provide unpaid care
Trafford (LAD), Census 2021
The PCN records 387 patients on the severe mental illness register (0.8%; England 1.0%), alongside 19 catchment care homes with 809 beds. In wider borough data, Trafford (LAD) recorded an 8.7% unpaid care rate (ranking 34 of 39 North West local authorities) and 8 rough sleepers in the autumn 2025 snapshot; these local authority measures do not describe GP registered lists.
Severe mental illness: physical health checks
Recorded severe mental illness prevalence is 0.8% (Trafford (LAD) 1.1%, England 1.0%). Published checks show 86.8% had blood pressure recorded, 86.8% BMI, and 85.9% alcohol status. Unrecorded components could reflect incomplete annual health checks, testable by audit.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,775
Hypertension register
+8.80%
Register growth, 3 yrs
Trafford (LAD) +4.39% · England +5.60%
−2.35pp
BP control, under 80
≤140/90 · +1.95pp aged 80+
+1,165
More patients by 2030
Forecast 7,940 (16.49%)
Hypertension case-finding and control
Recorded hypertension prevalence is 13.9% (6,775 patients), below Trafford (LAD) (15.1%), NHS Greater Manchester Integrated Care Board (14.4%) and England (15.2%). While 91.0% of patients have a recent blood pressure check (Trafford (LAD) 90.4%, England 90.0%), blood pressure control among patients under 80 is 64.5%, trailing Trafford (LAD) (66.5%), NHS Greater Manchester Integrated Care Board (68.6%) and England (67.8%). Furthermore, control in this under-80 group fell 3.5% over 2023 to 2025, whereas England rose +3.2%. Under-80 blood pressure control is lower than comparators and falling, which could reflect follow-up or treatment escalation gaps, testable by recall audit.
Lipids and statins
For patients with QRISK ≥ 20%, 62.8% receive lipid-lowering therapy, below Trafford (LAD) (67.1%) and England (63.6%), despite three-year growth of +12.4% over 2023 to 2025 (England +6.2%). Statin therapy in diabetes with cardiovascular disease reaches 81.8% (England 84.4%). Lower statin coverage in high-risk cohorts could reflect recall gaps, testable by clinical review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 74,650 | £2.30 | £1.94 | £1.86 | £171,695 |
| Cardiovascular (all), 2025 | 103,373 | £3.57 | £3.15 | £3.33 | £369,042 |
In 2026, the PCN prescribed 74,650 lipid-regulating drug items at £2.30 per item, compared with £1.98 in Trafford (LAD), £1.94 in NHS Greater Manchester Integrated Care Board, and £1.86 in England (£32,846 more than at England's unit cost). Differences in unit cost do not establish clinical inefficiency. Spend per item suggests an opportunity to review local lipid prescribing choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.25%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.50%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.4% (2,932 patients; England 6.6%), and COPD prevalence is 1.3% (649 patients; England 1.9%). Annual asthma reviews stand at 59.1% (Trafford (LAD) 63.7%, England 65.7%), leaving an estimated 1,199 patients unreviewed, while reviews fell 0.2% over 2023 to 2025 (England +4.4%). COPD reviews fell 7.0% over 2023 to 2025 (England +2.8%) to 71.5% (Trafford (LAD) 75.3%, England 76.4%). Lower review rates could reflect recall capacity gaps, unverified locally and testable by recall audit.
Cancer register and children's immunisation
Cancer prevalence is 4.7% (2,296 patients; England 3.8%). In Q1 2025/26 childhood immunisation, age-five MMR dose 2 reaches 95.6% (England 82.8%), exceeding the 95.0% target. However, 24-month MMR dose 1 is 88.8% (England 88.3%) and age-five 4-in-1 booster coverage is 87.7% (England 80.9%), both below the 95.0% target. Coverage below target highlights an opportunity to strengthen pre-school booster recall.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
Across NHS Greater Manchester ICB in 2022, 55.6% of staged cancers (6,491 of 11,679) were diagnosed at stage 1 or 2, compared with 55.3% in England, against the 75.0% national ambition by 2028 (about 2,270 extra early-stage cases required annually across the ICB). Staging was known for 70.8% of registered cancers (11,679 of 16,492). For the PCN, breast screening coverage reached 79.9% (England 69.9%) and cervical screening was 74.9% (England 66.8%). These system-level figures reflect wider cancer registration rather than PCN performance. System-wide staging gaps highlight that maintaining high screening participation across member practices is essential to support earlier diagnosis.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data at Manchester University NHS Foundation Trust, the cancer 62-day referral to treatment standard was 72.8% (standard 85.0%), trailing Northern Care Alliance NHS Foundation Trust (78.6%), NHS Greater Manchester Integrated Care Board (75.7%) and Stockport NHS Foundation Trust (74.7%), but above England (71.2%). The trust met the 28-day faster diagnosis standard at 80.1% (standard 75.0%), while 14.7% waited 6+ weeks for computed tomography (England 9.9%). These provider figures reflect acute system performance rather than PCN delivery. Secondary care waits may delay pathways, making primary care safety-netting important.
| Pathways within standard (%) | Manchester | Northern Care Alliance | Stockport | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 75.20 | 83.21 | 79.53 | 79.32 |
| 31-day treatment (96%) | 92.54 | 94.54 | 97.39 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 78.65 | 74.67 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | Northern Care Alliance | Stockport | England |
|---|---|---|---|---|
| MRI | 11.68 | 5.09 | 1.41 | 21.40 |
| CT | 14.66 | 4.10 | 2.93 | 9.92 |
| Echocardiography | 4.91 | 31.48 | 17.46 | 28.48 |
| Colonoscopy | 4.51 | 40.04 | 5.53 | 30.83 |
| Gastroscopy | 29.35 | 36.48 | 5.31 | 29.02 |
| All 15 DM01 tests | 8.98 | 15.71 | 14.08 | 23.14 |
| Community services activity | Trafford residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 41,705 | 573,310 |
| Referrals | 7,445 | 94,470 |
| Patients with a contact | 13,840 | 183,535 |
Community services (residents of Trafford), Jun 2026 (provisional). In provisional June 2026 Community Services Dataset records, adults aged 65 and over accounted for 51.3% of community service contacts among Trafford residents (21,375 of 41,705 contacts). This borough-level measure describes wider resident activity rather than PCN activity. This concentration highlights an opportunity to coordinate with local community nursing teams on cancer rehabilitation and supportive care.
Practice variation and patient experience
Practice variation and patient experience
Overall QOF achievement in 2025/26 ranges from 93.6% at St Johns Medical Centre to 99.7% at Altrincham Medical Practice (England 92.5%). However, vaccination and immunisation achievement varies by 49.2 pp, from 50.8% at West Timperley Medical Centre to 100.0% at Park Medical Practice (England 55.2%), showing variation across practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| St Johns | 125 | 0.0 | 56.5% | 75.2% | 88.4% |
| Shay Lane | 105 | 0.0 | 55.1% | 81.4% | 87.1% |
| Altrincham | 124 | 0.0 | 63.2% | 71.3% | 82.9% |
| Park Medical | 118 | 3.9 | 57.0% | 71.5% | 82.9% |
| West Timperley | 111 | 0.0 | 38.3% | 75.9% | 71.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Eleven of 25 tracked three-year trends trail England, led by falling chronic reviews
Eleven of 25 tracked three-year trends trail England. The widest lags are in chronic condition reviews and control: heart failure reviews fell 1.0% (England +8.7%), COPD reviews fell 7.0% (England +2.8%), and blood pressure control in patients under 80 fell 3.5% (England +3.2%). Conversely, notable strengths include breast screening coverage (+21.1% vs +8.4% England), QRISK ≥ 20% lipid therapy (+12.4% vs +6.2% England), and severe mental illness blood pressure checks (+8.6 pp vs +4.4 pp England). This divergence may reflect follow-up capacity constraints, which local recall audit could test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
BP control, under 80
Asthma reviews
Hypertension treated to target
Breast screening (53-70)
QRISK statin treatment
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Trafford (LAD) | Asset | PCN | Trafford (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 19 (809 beds) | n/a | Schools (catchment) | 58 | n/a |
| Children's centres | 7 | 16 | Places of worship | 58 | 119 |
| Libraries | 3 | 9 | Primary schools (LA maintained) | 14 | 39 |
| Primary academies | 5 | 17 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
59.1% reviewed (England 65.7%, Trafford (LAD) 63.7%); 1,199 of 2,932 registered patients unreviewed. For discussion, practices could run a single-template recall audit and offer flexible review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Heart failure register coding validation
Recorded prevalence is 0.8% (374 patients on the 47,655 list) vs 1.1% in Trafford (LAD) and England (gap +147 to +149). For discussion, practices could search clinical records for uncoded heart failure diagnoses or relevant prescribing, starting at Park Medical Practice (3.9% Core20). Low cost, quick to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register validation (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check audit (p4) | Severe mental illness: QOF prevalence | MHIS · From Harm to Hope | PCN |
| Hypertension control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Heart failure register coding validation (p12) | Heart failure register · Heart Failure: QOF prevalence · Registered population | — | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
